Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: J Public Econ. 2023 Mar 17;221:104860. doi: 10.1016/j.jpubeco.2023.104860

Figure 2 – Annual Views per Person of TV Ads for Top 200 Brand Name Drugs, for Non-Elderly.

Figure 2 –

Notes: Sample means from Nielsen Ad*Views in above median elderly share markets relative to below median elderly share markets. The vertical lines represent the dates when Part D was signed into law (December 2003) and was implemented (January 2006). Means are plotted for a balanced panel of the top 200 advertised brand-name drugs. There is a secular downward trend in overall views per person due to patent expirations of several of these drugs over this time period (in particular, four of the top 200 drugs went off patent around 2006: Pravachol, Wellbutrin XL, Zocor, and Zoloft). The downward trend in views matches the pattern in national advertising expenditures shown in Figure 1. In Appendix Figure B.2, we exclude all drugs that went off-patent during the study period.